Hvsen Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 188 million yuan, an increase of 494.28%
Hvsen Biotech released its Q3 2025 report, with operating revenue for the first three quarters reaching 1.26 billion yuan, a year-on-year increase of 58.92%; net profit attributable to the parent company was 188 million yuan, a year-on-year increase of 494.28%; net profit excluding non-recurring gains and losses was 166 million yuan, a year-on-year increase of 611.92%; basic earnings per share were 1.0134 yuan
According to the Zhitong Finance APP, Hvsen Biotech (300871.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.26 billion yuan, a year-on-year increase of 58.92%. The net profit attributable to shareholders of the listed company was 188 million yuan, a year-on-year increase of 494.28%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 166 million yuan, a year-on-year increase of 611.92%. The basic earnings per share were 1.0134 yuan
